OOO " Jodas Expoim" Pharmaceutical Import Profile — Russia (DGFT 2022–2026)

Name: OOO " Jodas Expoim" Pharmaceutical Import Records from India — 20 Products, $10.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

OOO " Jodas Expoim" — Pharmaceutical Importer Profile (2026) | 20 Products, $10.6M Trade | TransData Nexus

OOO " Jodas Expoim"

Pharmaceutical Importer · Russia · Advanced Oncology Focus · $10.6M Total Trade · DGFT Verified

OOO " Jodas Expoim" is a pharmaceutical importer based in Russia with a total trade value of $10.6M across 20 products in 6 therapeutic categories. Based on 217 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. OOO " Jodas Expoim" sources from 1 verified Indian supplier, with Jodas Expoim Private Limited accounting for 100.0% of imports.

OOO " Jodas Expoim" — Import Portfolio & Supplier Network

OOO " Jodas Expoim" import network — 20 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to OOO " Jodas Expoim"?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Jodas Expoim Private Limited	$2.2M	45	100.0%

OOO " Jodas Expoim" sources from 1 verified Indian supplier across 15 distinct formulations. The sourcing is highly concentrated — Jodas Expoim Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does OOO " Jodas Expoim" Import?

Formulation	Value	Ships
Omeprazole lyophilisate for	$350.0K	7
Capecitabine tablets USP 500MG (120	$300.0K	6
Cefotaxime sodium powder for solution	$250.0K	5
Cefuroxime powder for preparation for	$200.0K	4
Polymyxin b lyophilisate for	$200.0K	4
Ampicillin and sulbactam for injection	$160.6K	4
Gemcitabine lyophilizate for	$150.0K	3
Tigecycline lyophilisate for	$150.0K	3
Fluconazole infusion BP 2MG/ML-	$100.0K	2
Acyclovir lyophilized for preparation	$100.0K	2
Urapidil solution for intravenous	$50.0K	1
Amoxicillin & sulbactam for injection	$50.0K	1
Diatrizoate meglumine and diatrizoate	$50.0K	1
Paracetamol infusion BP 10MG/ML-	$50.0K	1
Esomeprazole sodium lyophilized for	$50.0K	1

Import Portfolio — Top 20 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Paclitaxel	Oncology	$1.8M	35	0.9%	2
2	Oxaliplatin	Advanced Oncology	$1.4M	29	1.7%	2
3	Imatinib	Advanced Oncology	$1.2M	24	1.4%	5
4	Gemcitabine	Oncology	$1.1M	23	1.0%	15
5	Docetaxel	Oncology	$700.0K	14	0.8%	6
6	Ertapenem	Advanced Antibiotics	$650.0K	13	0.6%	5
7	Temozolomide	Advanced Oncology	$650.0K	13	1.3%	4
8	Syringe	Medical Devices & Diagnostics	$500.0K	10	0.3%	13
9	Capecitabine	Advanced Oncology	$450.0K	9	0.3%	4
10	Amphotericin	Antifungals	$400.0K	8	0.5%	19
11	Tobramycin	Antibiotics	$300.0K	6	0.8%	10
12	Pemetrexed	Advanced Oncology	$250.0K	5	0.3%	4
13	Sulfamethoxazole	Advanced Antibiotics	$225.5K	8	1.1%	15
14	Irinotecan	Oncology	$200.0K	4	0.5%	16
15	Anastrozole	Advanced Oncology	$200.0K	4	0.2%	4
16	Linezolid	Advanced Antibiotics	$150.0K	3	0.4%	5
17	Ceftazidime	Advanced Antibiotics	$143.5K	3	1.3%	6
18	Fulvestrant	Advanced Oncology	$100.0K	2	0.7%	8
19	Gefitinib	Advanced Oncology	$100.0K	2	1.5%	5
20	Teicoplanin	Advanced Antibiotics	$96.7K	2	1.5%	14

OOO " Jodas Expoim" imports 20 pharmaceutical products across 6 categories into Russia totaling $10.6M.

OOO " Jodas Expoim" — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

OOO "Jodas Expoim" is a pharmaceutical importer based in Russia, specializing in the procurement of finished pharmaceutical formulations from India. Established in 2006, Jodas Expoim has developed a significant presence in the Russian pharmaceutical market, focusing on the importation of oncology and critical care medications. The company operates as a primary wholesaler, sourcing a diverse range of pharmaceutical products to meet the therapeutic needs of the Russian healthcare system.

Headquartered in Russia, OOO "Jodas Expoim" collaborates closely with its Indian counterpart, Jodas Expoim Private Limited, which is based in Hyderabad, Telangana, India. This partnership facilitates the efficient importation and distribution of high-quality pharmaceutical formulations, ensuring a steady supply of essential medications to the Russian market. The company's strategic focus on oncology and critical care aligns with the growing demand for specialized treatments in Russia, positioning OOO "Jodas Expoim" as a key player in the importation and distribution of these critical therapeutic areas.

2Distribution Network

OOO "Jodas Expoim" maintains a robust distribution network within Russia, ensuring the efficient delivery of imported pharmaceutical products across the country. While specific warehouse locations are not publicly disclosed, the company is known to collaborate with local partners to build distribution networks across regions such as Latin America, Africa, Asia Pacific, Russia, CIS, and the Middle East. This extensive network enables the company to effectively serve various regions within Russia, meeting the diverse healthcare needs of the population.

The company's logistics capabilities are supported by its partnership with Jodas Expoim Private Limited in India, which operates state-of-the-art manufacturing facilities. These facilities are EU-GMP certified, WHO GMP certified, and PIC/S approved, ensuring the production of high-quality pharmaceutical formulations. This collaboration ensures a steady supply of essential medications to the Russian market, reinforcing OOO "Jodas Expoim"'s role as a key importer and distributor of pharmaceutical products.

3Industry Role

OOO "Jodas Expoim" plays a pivotal role in Russia's pharmaceutical supply chain as a primary wholesaler and importer. By sourcing finished pharmaceutical formulations from India, the company ensures the availability of essential medications, particularly in the oncology and critical care sectors. This strategic focus addresses the growing demand for specialized treatments in Russia, positioning OOO "Jodas Expoim" as a key player in the importation and distribution of these critical therapeutic areas.

The company's partnership with Jodas Expoim Private Limited in India facilitates the efficient importation and distribution of high-quality pharmaceutical formulations. This collaboration underscores OOO "Jodas Expoim"'s commitment to providing the Russian healthcare system with access to essential medications, thereby enhancing the overall quality of patient care.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — OOO " Jodas Expoim"

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

OOO "Jodas Expoim" demonstrates a high level of sourcing concentration, importing 100% of its pharmaceutical products from a single supplier: Jodas Expoim Private Limited in India. This exclusive partnership has resulted in a total import value of $10.6 million USD over 217 shipments, encompassing 20 products across six therapeutic categories. The top five products imported include Paclitaxel ($1.8 million, 0.9% share), Oxaliplatin ($1.4 million, 1.7% share), Imatinib ($1.2 million, 1.4% share), Gemcitabine ($1.1 million, 1.0% share), and Docetaxel ($700,000, 0.8% share).

This sourcing strategy indicates a strategic choice to maintain a streamlined supply chain and ensure consistent product quality. The exclusive relationship with Jodas Expoim Private Limited suggests a stable and reliable partnership, reducing the complexities associated with managing multiple suppliers. However, this concentration also exposes OOO "Jodas Expoim" to potential risks related to supply chain disruptions, such as production delays or regulatory changes affecting the sole supplier.

2Supply Chain Resilience

The resilience of OOO "Jodas Expoim"'s supply chain is closely tied to its exclusive partnership with Jodas Expoim Private Limited in India. This collaboration ensures a consistent supply of high-quality pharmaceutical formulations, supported by Jodas Expoim Private Limited's state-of-the-art manufacturing facilities, which are EU-GMP certified, WHO GMP certified, and PIC/S approved.

Importing Pharmaceuticals into Russia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Russia

1Regulatory Authority & Framework

In Russia, the regulation of pharmaceutical imports is governed by the Federal Service for Surveillance in Healthcare (Roszdravnadzor), which operates under the Ministry of Health of the Russian Federation. The primary legislation overseeing the circulation of medicines is the Federal Law No. 61-FZ "On Circulation of Medicines," enacted on April 12, 2010. This law outlines the procedures for the importation, registration, and distribution of pharmaceutical products within Russia.

The marketing authorization pathway for Indian generics involves obtaining a state registration certificate from Roszdravnadzor. This process includes the submission of comprehensive documentation, such as clinical trial data, quality control reports, and evidence of compliance with Good Manufacturing Practices (GMP). The registration ensures that imported pharmaceutical products meet the safety, efficacy, and quality standards required for the Russian market.

2Import Licensing & GMP

Import licensing requirements in Russia stipulate that all pharmaceutical products must be registered with Roszdravnadzor before they can be imported and distributed. This registration process involves the submission of detailed product dossiers, including information on manufacturing processes, quality control measures, and clinical efficacy. Additionally, the manufacturing facilities of the exporting company must hold valid GMP certificates recognized by Roszdravnadzor.

OOO " Jodas Expoim" — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

OOO "Jodas Expoim" focuses on importing pharmaceutical products in the oncology and critical care therapeutic areas. This strategic emphasis addresses the growing demand for specialized treatments in Russia, where there is an increasing prevalence of cancer and critical health conditions. By sourcing high-quality generic formulations from India, the company aims to provide affordable and effective treatment options to the Russian healthcare system.

The market demand for these products is driven by the need for

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — OOO " Jodas Expoim"

What products does OOO " Jodas Expoim" import from India?

OOO " Jodas Expoim" imports 20 pharmaceutical products across 6 categories. Top imports: Paclitaxel ($1.8M), Oxaliplatin ($1.4M), Imatinib ($1.2M), Gemcitabine ($1.1M), Docetaxel ($700.0K).

Who supplies pharmaceuticals to OOO " Jodas Expoim" from India?

OOO " Jodas Expoim" sources from 1 verified Indian suppliers. The primary supplier is Jodas Expoim Private Limited (100.0% of imports, $2.2M).

What is OOO " Jodas Expoim"'s total pharmaceutical import value?

OOO " Jodas Expoim"'s total pharmaceutical import value from India is $10.6M, based on 217 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does OOO " Jodas Expoim" focus on?

OOO " Jodas Expoim" imports across 6 categories. The largest: Advanced Oncology (41.1%), Oncology (35.7%), Advanced Antibiotics (11.9%).

Get Full OOO " Jodas Expoim" Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.